Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 276

1.

Appraisal of the role of radical prostatectomy for rhabdomyosarcoma in children: oncological and urological outcome.

Angelini L, Bisogno G, Esposito C, Castagnetti M.

Ther Adv Urol. 2018 Mar 7;10(6):189-196. doi: 10.1177/1756287218759883. eCollection 2018 Jun.

2.

Aquablation: a novel and minimally invasive surgery for benign prostate enlargement.

Taktak S, Jones P, Haq A, Rai BP, Somani BK.

Ther Adv Urol. 2018 Feb 26;10(6):183-188. doi: 10.1177/1756287218760518. eCollection 2018 Jun. Review.

3.

Analysis of psychosocial stress factors in patients with renal cancer.

Draeger DL, Sievert KD, Hakenberg OW.

Ther Adv Urol. 2018 Feb 18;10(6):175-182. doi: 10.1177/1756287218754766. eCollection 2018 Jun.

4.

Prostate artery embolization: a new, minimally invasive treatment for lower urinary tract symptoms secondary to prostate enlargement.

Maclean D, Maher B, Modi S, Harris M, Dyer J, Somani B, Hacking N, Bryant T.

Ther Adv Urol. 2017 Jul 10;9(8):209-216. doi: 10.1177/1756287217717889. eCollection 2017 Aug. Review.

5.

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

Rizzo M, Porta C.

Ther Adv Urol. 2017 Jun 29;9(8):195-207. doi: 10.1177/1756287217713902. eCollection 2017 Aug. Review.

6.

Optical improvements in the diagnosis of bladder cancer: implications for clinical practice.

Schubert T, Rausch S, Fahmy O, Gakis G, Stenzl A.

Ther Adv Urol. 2017 Sep 4;9(11):251-260. doi: 10.1177/1756287217720401. eCollection 2017 Nov. Review.

7.

Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer.

Cozzi G, Musi G, Bianchi R, Bottero D, Brescia A, Cioffi A, Cordima G, Delor M, Di Trapani E, Ferro M, Matei DV, Russo A, Mistretta FA, De Cobelli O.

Ther Adv Urol. 2017 Oct 9;9(11):241-250. doi: 10.1177/1756287217731449. eCollection 2017 Nov.

8.

Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.

Osanto S, van der Hulle T.

Ther Adv Urol. 2018 Jan 9;10(3):109-123. doi: 10.1177/1756287217748867. eCollection 2018 Mar. Review.

9.

The impact of comorbidities, sex and age on the occurrence of acute kidney injury among patients undergoing nephron-sparing surgery.

Hellou E, Bahouth Z, Sabo E, Abassi Z, Nativ O.

Ther Adv Urol. 2018 Jan 8;10(3):103-108. doi: 10.1177/1756287217747190. eCollection 2018 Mar.

10.

Urogenital tuberculosis, the cause of ineffective antibacterial therapy for urinary tract infections.

Kulchavenya E, Cherednichenko A.

Ther Adv Urol. 2017 Dec 22;10(3):95-101. doi: 10.1177/1756287217745772. eCollection 2018 Mar.

11.

Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects.

Abello A, Das AK.

Ther Adv Urol. 2018 Feb 22;10(5):165-173. doi: 10.1177/1756287218756082. eCollection 2018 May. Review.

12.

Intravesical instillations for the treatment of refractory recurrent urinary tract infections.

Dutta S, Lane F.

Ther Adv Urol. 2018 Feb 18;10(5):157-163. doi: 10.1177/1756287218757655. eCollection 2018 May.

13.

Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice.

Cwikla DJ, Yafi FA.

Ther Adv Urol. 2018 Feb 8;10(4):139-153. doi: 10.1177/1756287218755020. eCollection 2018 Apr. Review.

14.

Contemporary best practice urolithiasis in pregnancy.

Valovska MI, Pais VM Jr.

Ther Adv Urol. 2018 Feb 8;10(4):127-138. doi: 10.1177/1756287218754765. eCollection 2018 Apr. Review.

15.

Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.

Gacci M, Sebastianelli A, Spatafora P, Corona G, Serni S, De Ridder D, Gravas S, Abrams P.

Ther Adv Urol. 2017 Dec 7;10(2):79-92. doi: 10.1177/1756287217742837. eCollection 2018 Feb. Review.

16.

Circulating tumor cells in genitourinary tumors.

Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A.

Ther Adv Urol. 2017 Nov 22;10(2):65-77. doi: 10.1177/1756287217742564. eCollection 2018 Feb. Review.

17.

Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.

Meani D, Solarić M, Visapää H, Rosén RM, Janknegt R, Soče M.

Ther Adv Urol. 2017 Nov 23;10(2):51-63. doi: 10.1177/1756287217738985. eCollection 2018 Feb. Review.

18.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED.

Ther Adv Urol. 2017 Nov 22;10(2):43-50. doi: 10.1177/1756287217738150. eCollection 2018 Feb.

19.

Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy.

Abdel-Rahman O.

Ther Adv Urol. 2017 Nov 8;10(2):35-42. doi: 10.1177/1756287217737706. eCollection 2018 Feb.

20.

Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons.

Kosilov KV, Loparev S, Kuzina I, Prokofyeva A.

Ther Adv Urol. 2017 Oct 5;9(12):271-279. doi: 10.1177/1756287217731010. eCollection 2017 Dec.

Supplemental Content

Loading ...
Support Center